Neuphoria Therapeutics (NEUP) Return on Capital Employed (2024 - 2026)
Neuphoria Therapeutics (NEUP) reported Return on Capital Employed of 49.02% for Q1 2026, down 10680.0% year-over-year from N/an in Q1 2025, and down 303.33% on a QoQ basis from 12.15% in Q4 2025.
Neuphoria Therapeutics (NEUP) has 3 years of Return on Capital Employed data on file, last reported at 49.02% in Q1 2026.
- Quarterly Return on Capital Employed fell 10680.0% year-over-year to 49.02% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 49.02% (down 10680.0% YoY) and the FY2025 annual result came in at 4.72%, up 1132.0% from the prior year.
- Return on Capital Employed eased to 49.02% in Q1 2026 per NEUP's latest filing, from 12.15% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 57.78% in Q1 2025 and bottomed at 49.02% in Q1 2026.
- The 3-year median for Return on Capital Employed is 8.78% (2024), against an average of 5.27%.
- The widest annual swing landed in 2025, when Return on Capital Employed sank 529 bps; it then tumbled 10680 bps in 2026.
- Tracing NEUP's Return on Capital Employed over 3 years: stood at 6.22% in 2024, then tumbled by 95 bps to 12.15% in 2025, then slumped by 303 bps to 49.02% in 2026.
- Per Business Quant, the three latest NEUP Return on Capital Employed figures stand at 49.02% (Q1 2026), 12.15% (Q4 2025), and 14.07% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | Neuphoria Therapeutics | 28.35 Mn | 8.95 Mn | - | -49.02% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -49.02% |
| Dec 31, 2025 | -8.91% |
| Sep 30, 2025 | -9.90% |
| Jun 30, 2025 | -0.69% |
| Mar 31, 2025 | 57.78% |
| Dec 31, 2024 | -6.22% |
| Sep 30, 2024 | -8.78% |